IGF2BP1 and colorectal carcinoma: Mechanistically, M16-mediated m6A modifications enhance the stability of TM7SF2 mRNA via IGF2BP1- and IGF2BP2-dependent pathways, thereby facilitating lipid metabolic reprogramming and promoting CRC progression.